Newton001-Developing a partnership to inform UK-Brazil TB control:Investigating BCG vaccination efficacy following latent TB treatment (TBTVacc)

结核病（TB）是全球疾病负担的主要原因。我们计划研究在个体完成潜伏性结核病治疗后，卡介苗接种是否会导致人体对结核病的免疫力有所不同。这将使我们能够测试BCG是否可以在结核菌清除后保护个人。我们将在英国和巴西研究人员之间建立伙伴关系，以开展以下工作：审查和总结任何已发表的关于卡介苗评估治疗潜伏性结核病后保护作用的研究。我们将利用这些信息和专家意见，尝试量化结核病治疗后接种疫苗的影响。我们将组织两个研讨会，一个在巴西，一个在英国，以加强合作伙伴之间的现有合作。我们将利用这些研讨会来发展我们的试点研究，并计划申请一项重大试验的赠款。我们将确保在英国为巴西学生和在巴西的英国学生提供培训机会。我们将在巴西进行一项试点研究，以调查进行为期6个月的试验的可行性。这项试验性研究将在完成潜伏性结核病治疗后立即检查40人接种卡介苗后的免疫变化。

Tuberculosis (TB) is a major cause of the global disease burden. We plan to investigate whether the human immunity to tuberculosis as a result of BCG vaccination is different after individuals complete treatment for latent TB. This will allow us to test whether BCG can protect individuals following clearance of the tuberculosis bacterium. We would develop a partnership between UK and Brazilian researchers to undertake the following: Review and summarise any published studies of BCG assessing protection after treatment for latent TB. We will use this information and expert views to try and quantify the impact of vaccinating people after TB treatment.We would organise two workshops, one in Brazil and one in the UK that strengthen the existing collaboration between partners. We will use these workshops to develop our pilot study and to plan the grant application for a major trial. We would ensure there are training opportunities in the UK for Brazilian students, and UK students in Brazil.We will undertake a pilot study in Brazil to investigate the feasibility of undertaking a trial over a 6 month period. The pilot study would examine immunological changes after BCG vaccination in 40 people immediately following the completion of treatment for latent TB.